Hybrid Diabetes System Acts as Artificial Pancreas
By HospiMedica International staff writers Posted on 20 Jun 2017 |
Image: An illustration of the MiniMed 670G hybrid closed-loop system (Photo courtesy of Medtronic).
An innovative insulin pump and infusion patch automatically deliver basal insulin in order to control blood glucose levels in people with Type 1 diabetes (T1D).
The Medtronic (Dublin, Ireland) MiniMed 670G system is designed to deliver a variable rate bolus of insulin based on the personalized needs of the patient in order to maximize time within glucose target levels. The system is powered by the SmartGuard HCL algorithm, which self-adjusts the delivery of basal insulin every five minutes, 24 hours a day, based on real-time data gathered from the Guardian Sensor, an advanced glucose sensor that continuously monitors itself. Patients only need to enter mealtime carbohydrates, accept bolus correction recommendations, and periodically calibrate the sensor.
The system also features the Contour Next Link 2.4 blood glucose monitoring system (BGMS) from Ascensia (Parsippany, NJ, USA). Data from the pivotal trial of the MiniMed 670G system demonstrated less glycemic variability, more time in target range, less exposure to hypoglycemia and hyperglycemia, and reduced A1c for T1D patients on the system. Real-world use (as demonstrated during the customer training phase) showed consistent improved outcomes across several important areas, including Time in Range (74%) and greater median time in Auto Mode (92%).
“The MiniMed 670G system has proven to be life-changing for many patients who participated in the customer training phase and we are truly excited to be able to introduce it to many more who stand to benefit,” said Jennifer Lynn Sherr, MD, PhD, of the Yale School of Medicine. “The constant vigilance that this chronic medical condition imposes on both patients and their families is now relaxed and caregivers have a new level of independence and freedom. As someone who lives with type 1 diabetes, it's exciting to see this innovation alleviate much of the burden of managing this chronic disease.”
“The response from the diabetes community has been tremendously positive, and we are proud to be leading this remarkable period in diabetes history in partnership with the clinical and advocacy communities,” said Alejandro Galindo, president of the intensive insulin management division within the Diabetes Group at Medtronic. “We've essentially designed a smarter insulin pump that alleviates some of the burden associated with diabetes management, which can be unrelenting and exhausting.”
T1D is an autoimmune disease in which a person's pancreas stops producing insulin. It can impact both children and adults at any age, causing dependence on multiple daily injections of insulin or an insulin pump. The complications stemming from high and low blood sugar levels can lead to serious short and long-term results including kidney failure, blindness, nerve damage, heart attack, stroke, and pregnancy complications. Lows can be life-threatening, particularly at night when they are most difficult to manage.
The Medtronic (Dublin, Ireland) MiniMed 670G system is designed to deliver a variable rate bolus of insulin based on the personalized needs of the patient in order to maximize time within glucose target levels. The system is powered by the SmartGuard HCL algorithm, which self-adjusts the delivery of basal insulin every five minutes, 24 hours a day, based on real-time data gathered from the Guardian Sensor, an advanced glucose sensor that continuously monitors itself. Patients only need to enter mealtime carbohydrates, accept bolus correction recommendations, and periodically calibrate the sensor.
The system also features the Contour Next Link 2.4 blood glucose monitoring system (BGMS) from Ascensia (Parsippany, NJ, USA). Data from the pivotal trial of the MiniMed 670G system demonstrated less glycemic variability, more time in target range, less exposure to hypoglycemia and hyperglycemia, and reduced A1c for T1D patients on the system. Real-world use (as demonstrated during the customer training phase) showed consistent improved outcomes across several important areas, including Time in Range (74%) and greater median time in Auto Mode (92%).
“The MiniMed 670G system has proven to be life-changing for many patients who participated in the customer training phase and we are truly excited to be able to introduce it to many more who stand to benefit,” said Jennifer Lynn Sherr, MD, PhD, of the Yale School of Medicine. “The constant vigilance that this chronic medical condition imposes on both patients and their families is now relaxed and caregivers have a new level of independence and freedom. As someone who lives with type 1 diabetes, it's exciting to see this innovation alleviate much of the burden of managing this chronic disease.”
“The response from the diabetes community has been tremendously positive, and we are proud to be leading this remarkable period in diabetes history in partnership with the clinical and advocacy communities,” said Alejandro Galindo, president of the intensive insulin management division within the Diabetes Group at Medtronic. “We've essentially designed a smarter insulin pump that alleviates some of the burden associated with diabetes management, which can be unrelenting and exhausting.”
T1D is an autoimmune disease in which a person's pancreas stops producing insulin. It can impact both children and adults at any age, causing dependence on multiple daily injections of insulin or an insulin pump. The complications stemming from high and low blood sugar levels can lead to serious short and long-term results including kidney failure, blindness, nerve damage, heart attack, stroke, and pregnancy complications. Lows can be life-threatening, particularly at night when they are most difficult to manage.
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure